OBI Pharma (4174.TWO) Earnings Analysis
OBI Pharma (4174.TWO) next reports earnings on 2026-07-31, consensus EPS -8.8 TWD. Last quarter (2026-03-09) it missed with EPS -18.8 TWD vs -5.14 TWD est (-265.8%). It has beaten estimates in 0/2 recent quarters (0%). Trailing P/E -0.90.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 4174.TWO next report earnings?
| Next earnings date | 2026-07-31 |
|---|---|
| Consensus EPS estimate | -8.8 TWD |
| Revenue estimate | 0.01B |
4174.TWO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-09 | -18.8 TWD | -5.14 TWD | -265.8% | Miss |
| 2025-09-30 | -3.56 TWD | -2.75 TWD | -29.5% | Miss |
| 2025-08-04 | -4.96 TWD | n/a | n/a | n/a |
| 2025-05-08 | -3.9 TWD | n/a | n/a | n/a |
| 2025-03-10 | -6.05457 TWD | n/a | n/a | n/a |
| 2024-11-04 | -4.51317 TWD | n/a | n/a | n/a |
| 2024-08-02 | -4.71682 TWD | n/a | n/a | n/a |
Beat rate: 0/2 (0%) over reported quarters with consensus data.
4174.TWO valuation and analyst view
| Trailing P/E | -0.90 |
|---|---|
| Trailing EPS | -15.07164 TWD |
| Price / book | 2.49 |
| Dividend yield | 0.00% |
| Market cap | 3.69B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is OBI Pharma (4174.TWO)'s next earnings date?
OBI Pharma is next scheduled to report on 2026-07-31, with a consensus EPS estimate of -8.8 TWD and revenue estimate of 0.01B.
Did 4174.TWO beat earnings last quarter?
In its 2026-03-09 report, 4174.TWO posted EPS of -18.8 TWD versus a -5.14 TWD estimate — a miss of 265.8%.
What is 4174.TWO's earnings track record?
Over the last 2 reported quarters with consensus data, 4174.TWO beat estimates 0 times (0%).
What is 4174.TWO's current P/E ratio and EPS?
4174.TWO trades at a trailing P/E of -0.90 on trailing EPS of -15.071640428929957 TWD.
What do analysts rate 4174.TWO?
4174.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.